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Figure 1. Changes in subchondral bone density from baseline at one and two
years after ankle distraction for individual patients.
chondral bone density that persisted for at least two years of
follow-up. This could lead to a more physiologically normal distribu-
tion of mechanical stresses by the less dense bone, encouraging
cartilage repair activity. As such, these prolonged bone changes
may in part explain the clinical beneﬁts of joint distraction.
This study was ﬁnancially supported by grants from the NIH/
NIAMS (AR048939 and AR055533).
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Purpose: The proteinase-activated receptor-2 (PAR-2), member
of the G protein coupled receptor family, was demonstrated to
be implicated in human osteoarthritis (OA) cartilage catabolism
and subchondral bone remodeling.To validate the results of these
in vitro studies, we investigated the in vivo role of PAR-2 in the
development of cartilage and subchondral bone changes in OA
using a mouse model.
Methods: Osteoarthritis was induced by partial medial menis-
cectomy of the right knee using a microsurgical technique in
C57Bl/6 wild-type (WT) and PAR-2 knock-out (PAR-2 KO) mice.
Knee swelling was measured twice a week for the entire duration
of the study (8 weeks) with a digital calliper. Histological evalua-
tion assessing cartilage structure, cellularity, matrix staining and
remodelling in the deep zone (global score corresponding to the
sum of the different criteria), as well as morphometric evaluation of
the subchondral bone were performed at 4 and 8 weeks and val-
ues compared to control. A comparison between WT (n=9-10 per
group) and PAR-2 KO (n=5-9 per group) mice was also performed.
Results: Knee swelling was observed in the WT immediately fol-
lowing surgery and increased with time (until week 8). The knee
swelling of the PAR-2 KO mice was signiﬁcantly lower (p<0.0001)
at both 4 and 8 weeks post-surgery than the WT group. Both WT
and PAR-2 KO mice demonstrated cartilage damage at 4 and 8
weeks post-surgery; however, lesions were less severe in the PAR-
2 KO mice (p<0.03 on the global score). More speciﬁcally, com-
pared to PAR-2 KO mice, WT mice had more severe alterations of
the cartilage structure at 4 and 8 weeks post-surgery (p<0.0001
and p<0.02, respectively), a higher hypocellularity (p<0.003), and
a signiﬁcant loss of cartilage (p<0.04) as shown by cartilage thick-
ness measurement. Yet, no signiﬁcant differences in the structural
changes in the deep zone of cartilage and in the subchondral
bone were found in either WT or PAR-2 KO mice. However, con-
trol (unoperated) PAR-2 KO mice had less bone surface than the
autologous WT mice (p<0.04).
Conclusions: This study is the ﬁrst to demonstrate the in vivo
implication of PAR-2 in the development of experimental OA,
thus conﬁrming its involvement in OA structural changes. It also
showed that PAR-2 plays a role on subchondral bone that needs
to be further explored. Consequently, these ﬁndings reinforce the
therapeutic potential of a PAR-2 antagonist for the treatment of OA.
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EFFICACY OF CHONDROTIN SULPHATE ON SYNOVITIS IN
PATIENTS WITH KNEE OSTEOARTHRITIS: AN
ULTRASOUND STUDY
I. Möller
Inst. Poal de Reumatología, Barcelona, Spain
Purpose: Synovitis (as deﬁned by hypertrophy and effusion) is
common in osteoarthritis and may be important in both pain
and structural progression. In addition, chondroitin sulphate (CS)
treatment has been associated with a signiﬁcant decrease in
the incidence of joint swelling, effusion or both. The aim of this
study was to assess the efﬁcacy of CS alone or in combination
with glucosamine sulfate (GS) on synovitis in patients with knee
osteoarthritis (KOA).
Methods: Retrospective study involving 115 outpatients with syn-
ovitis who received CS 800 mg (N=36) (Condrosan®, Bioibérica
S.A., Barcelona), CS 800 mg + SG 1500 mg (N=41) (Cartisorb®,
Bioibérica S.A., Barcelona) or acetaminophen (ACET) 500 mg
(N= 38) for their KOA on a daily basis for a 6-month period.
Synovitis was measured in the suprapatellar recess using ultra-
sonography (US) equipment with a high frequency linear array.
The maximal synovial thickness and effusion depth were mea-
sured in millimeters using the longitudinal axis. Synovitis was
deﬁned as present in measures ≥4 mm. Furthermore, knee pain
according to Huskisson’s VAS, extra acetaminophen consumption
and the presence of meniscal extrusion and Baker’s cyst were
also assessed. Patient’s follow-up was performed after 1, 2, 3 and
6 months of treatment.
Results: From the 115 included subjects, 111 (96,5%) were
female, had a mean age (SD) of 62,4 (10,8) years, mean BMI
(SD) of 27,4 (4,5) kg/m2, 20 (17,4%) presented Baker’s cyst and
13 (11,3%) meniscal extrusion. The mean synovitis (SD) was 6,3
(1,3) mm and the mean knee pain (SD) was 6,5 (1,8) mm. Patients
in all groups had similar baseline characteristics.
Among all the included subjects, a positive correlation between
BMI and the size of synovitis (r=0,138; p=0,002) and knee pain
(r=0,136; p=0,003) was noted. In addition, a positive correlation
between synovitis and knee pain (r=0,385; p=0,000) was also
detected.
Regarding US assessments, the three treatment groups experi-
enced a decrease in synovitis over time. However, patients treated
with SYSADOAs reached physiological mean values after the
second month of treatment. This improvement in synovitis was
maintained in the course of treatment with a mean synovitis (SD)
of 3,2 (2,7) mm in the CS group and of 2,9 (2,6) mm in the
CS+SG group after 6 months of treatment. Multiple comparisons
between groups, showed a signiﬁcant decrease in synovitis after
SYSADOA therapy vs ACET treatment after the ﬁrst month of
follow-up.Statistical analysis demonstrated a faster decrease in
knee pain with CS vs ACET (p= 0,000) and in the CS + SG
group vs ACET (p=0,000). Analysis at each visit for the decrease
in pain scores showed that the differences between CS+ SG vs
ACET were signiﬁcant after the ﬁrst month of treatment (p=0,037)
and between CS vs ACET after the second month of treatment
(p=0,017).
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Conclusions: Preliminary data of this study suggest that CS
alone or in combination with GS is able to decrease signiﬁcantly
synovitis as measured by US. The decrease in synovitis after
SYSADOA treatment has been correlated with an improvement
in knee pain. The decrease in synovitis elicited by SYSADOA
treatment in this retrospective study is in accordance with former
reduction of synovitis signs shown by CS in other studies and
could contribute to explain its symptomatic and structure disease
modifying effects.
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Purpose: To determine the associations between serum levels of
inﬂammatory markers, radiographic osteoarthritis (OA) and knee
cartilage loss over time in older adults.
Methods: A total of 193 randomly selected subjects (mean 63
years, range 51-78, 47% female) were studied at baseline and 2.9
years later. Serum high-sensitivity C-reactive protein (hs-CRP),
interleukin 6 (IL-6) and tumor necrosis factor α (TNF-α) were as-
sessed by radioimmunoassay. T1-weighted fat-suppressed MRI of
the right knee was performed to determine knee cartilage volume.
Knee radiographic osteoarthritis (ROA) was also assessed.
Results: At baseline, quartiles of IL-6 and TNF-α were associated
with increased prevalence of medial tibiofemoral joint space nar-
rowing (grade ≥1) in multivariable analyses (IL-6: OR=1.41 and
1.49 per quartile; TNF-α: OR=1.62 and 1.49 per quartile for right
and left knees, respectively; all P<0.05). Longitudinally, baseline
IL-6 (not TNF-α) predicted loss in both medial and lateral tibial
cartilage volume (β: -0.87% and -1.02% per annum per quar-
tile, P<0.05 and P<0.01, respectively). An increase in IL-6 was
associated with increased loss of medial and lateral tibial carti-
lage volume (β: -0.89% and -0.78% per annum per quartile, both
P<0.05), and change in TNF-α was also negatively associated
with change in medial and lateral tibial cartilage volume (β: -0.75%
and -0.80% per annum per quartile, both P<0.05). The associa-
tions of IL-6 and TNF-α were dependent, in part, on each other
except those between baseline IL-6 and cartilage loss. Serum
hs-CRP was not associated with ROA and cartilage loss.
Conclusions: Serum levels of IL-6 and, to a lesser extent, TNF-α
are associated with knee cartilage loss in older people suggesting
low level inﬂammation plays a role in the pathogenesis of knee
OA.
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RACIAL DIFFERENCES IN OSTEOARTHRITIS PAIN AND
FUNCTION: POTENTIAL EXPLANATORY FACTORS
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Purpose: African Americans with osteoarthritis (OA) report greater
pain and functional limitations than Caucasians, but the reasons
for these racial disparities are not well understood. This study
examined factors underlying racial differences in pain and function
among patients with hip and/or knee osteoarthritis (OA), including
psychological variables that have not previously been examined in
this context.
Methods: Participants were n=491 African Americans and Cau-
casians enrolled in a clinical trial of telephone-based OA self-
management. All measures were obtained at baseline. Pain and
function were assessed using the Arthritis Impact Measurement
Scales-2 (AIMS2) subscales. Potential explanatory variables in-
cluded demographic factors (age, gender, marital status, educa-
tion, income, working status, health literacy), health-related factors
(body mass index, self-reported health, joint(s) with OA, duration
of OA symptoms, pain medication use, current exercise), and
psychological factors (arthritis self-efﬁcacy, problem- and emotion-
focused pain coping, AIMS2 affect subscale). The AIMS2 pain
subscale was also included in models of AIMS2 function. Potential
explanatory variables that were associated with both race and
pain or function, and that reduced the association of race with
pain or function by ≥10%, were included in the ﬁnal multivariable
linear regression models where racial differences in AIMS2 pain
and function scores were examined.
Results: In unadjusted linear regression models, African Ameri-
can race was associated with higher (worse) AIMS2 pain scores
(unadjusted B = 0.65, p<0.01) and higher (worse) AIMS2 func-
tion scores (unadjusted B = 0.59, p<0.01). African American race
was no longer signiﬁcantly associated with AIMS2 pain scores in
the ﬁnal regression model (B = 0.03, p=0.874); variables signif-
icantly associated with worse AIMS2 pain scores in that model
were: worse AIMS2 affect scores, greater emotion-focused cop-
ing, lower arthritis self-efﬁcacy, and fair or poor self-reported
health. African American race was also no longer signiﬁcantly
associated with AIMS2 function scores in the ﬁnal regression
model (B = 0.07, p=0.509). Variables signiﬁcantly associated with
worse AIMS2 function scores were the same as those described
above for AIMS2 pain scores. In addition, worse AIMS2 pain
scores were signiﬁcantly associated with worse AIMS2 function
scores.
Conclusions: Factors explaining racial differences in pain and
function were largely psychological, including AIMS2 affect (which
comprises mood and level of tension), use of emotion-focused
coping, and arthritis self-efﬁcacy. Self-management and psycho-
logical/behavioral interventions can inﬂuence these factors, and
greater dissemination of these programs among African Amer-
icans may be a key step toward reducing racial disparities in
OA-related pain and function.
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CHONDROCYTES
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Purpose: MicroRNAs are small non-coding RNAs that regulate
target messenger RNA. We investigated the implication of two
miRNAs, miR-140 and miR-27a, in MMP-13 and IGFBP-5 gene
regulation in human osteoarthritic (OA) chondrocytes.
Methods: Gene expression was determined by real-time PCR.
The effect of each miRNA on IGFBP-5 and MMP-13 expres-
sion/production was evaluated by transiently transfecting their pre-
cursors (pre-miRNAs) and inhibitors (anti-miRNAs) into human
OA chondrocytes. Modulation of IGFBP-5, miR-140 and miR-27a
